2564-95-6

Usage

Uses

It is employed as a intermediate for pharmaceutical.

InChI:InChI=1/C6H11NO3/c1-7(2)5(8)3-4-6(9)10/h3-4H2,1-2H3,(H,9,10)/p-1

Upstream product

• 108-30-5 succinic acid anhydride 
• 124-40-3 dimethyl amine 
• 68-12-2 N,N-dimethyl-formamide 
• 110-15-6 succinic acid 
• 506-59-2 N,N-dimethylammonium chloride 
• 2680-03-7 N,N-Dimethylacrylamide 
• 3495-36-1 cesium formate 

Downstream Products

• 13330-96-6 4-dimethylamino-1-butanol 
• 23159-09-3 N',N'-dimethyl-N-carbobenzoxy-β-alaninamide 
• 30891-38-4 N-(4-Dimethylamino-butyl)-3-(4-methoxy-phenyl)-N-methyl-propionamide 
• 29802-83-3 (E)-N-(4-Dimethylamino-butyl)-3-(4-methoxy-phenyl)-N-methyl-acrylamide 
• 1421066-87-6 C₃₀H₄₁N₃O₃ 

Relevant academic research and scientific papers

Photoredox Activation of Formate Salts: Hydrocarboxylation of Alkenes via Carboxyl Group Transfer

A photoredox activation mode of formate salts for carboxylation was developed. Using a formate salt as the reductant, carbonyl source, and hydrogen atom transfer reagent, a wide range of alkenes can be converted into acid products via a carboxyl group tra

New succinate derivatives

The invention relates generally to new compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 are independently of one another and denote hydrogen, hydroxyl, C1- C6-alkyl group or R6 and R7 form together a C5-C6 ring system, and wherein n = 0, 1, 2,

NEW SUCCINATE DERIVATIVES

The invention relates generally to new compounds of formula (I), wherein R1, R'1, R2, R'2, R3, R'3, R4 R'4, R5, R'5, R6, R7

Synthesis and antiischemic activity of dicarboxylic nitroxyalkylamides and nitroxyalkylimides

A number of dicarboxylic N-(2-nitroxyalkyl)amides and N-(2-nitroxyalkyl)imides were synthesized and their antiischemic activity was studied. The ratio of the areas of necrotic and ischemic zones was used as a criterion for evaluation of antiischemic activity. The maximum values were close to antiischemic activity of Nicorandil, with acute toxicity of compounds synthesized being considerably lower.

Esteramide prodrugs of anti-inflammatory corticosteroids

Transient, C-21 and/or C-17 esteramide prodrugs of the anti-inflammatory corticosteroids, prepared by esterification of hydroxy steroids, are disclosed.